Sweden's Oncopeptides Q4 sales rise 88%

Oncopeptides AB

19/02/2026 07:09

Overview

Swedish biotech firm's Q4 net sales rose 88% yr/yr to SEK 18.6 mln

Company reported Q4 net loss and negative EPS

Company announced SEK 200 mln rights issue to bolster financial position

Outlook

Oncopeptides anticipates reaching positive cash flow in 2027

Company aims for profitability in Germany during 2026

Oncopeptides announces rights issue of up to SEK 200 mln

Result Drivers

PEPAXTI DEMAND - Strong demand for Pepaxti, especially in Italy, drove Q4 sales growth, exceeding initial expectations

PLATFORM EXPANSION - Company plans to expand PDC platform beyond multiple myeloma into other diseases, including glioblastoma

GERMAN MARKET CHALLENGES - Slower uptake in Germany and a medical strike in Spain affected sales growth, leading to strategic review

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 18.57 mln
Q4 Adjusted EPS
-SEK 0.25
Q4 Net Income
-SEK 65.17 mln
Q4 Adjusted Free Cash Flow
-SEK 60.06 mln
Q4 Operating Profit
-SEK 61.53 mln


Analyst Coverage

Wall Street's median 12-month price target for Oncopeptides AB is SEK5.18, about 88.5% above its February 18 closing price of SEK2.75

Press Release: ID:nMFN9vWYP6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)